# reload+after+2024-01-20 22:45:41.588586
address1§12730 High Bluff Drive
address2§Suite 400
city§San Diego
state§CA
zip§92130
country§United States
phone§858 500 8800
website§https://kuraoncology.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
fullTimeEmployees§131
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Troy Edward Wilson J.D., Ph.D.', 'age': 54, 'title': 'Chairman, CEO & President', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 1061902, 'exercisedValue': 0, 'unexercisedValue': 775556}, {'maxAge': 1, 'name': 'Ms. Kathleen  Ford', 'age': 76, 'title': 'Chief Operating Officer', 'yearBorn': 1947, 'fiscalYear': 2022, 'totalPay': 754239, 'exercisedValue': 0, 'unexercisedValue': 18204}, {'maxAge': 1, 'name': 'Dr. Stephen  Dale M.D.', 'age': 51, 'title': 'Chief Medical Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 684415, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas  Doyle', 'age': 52, 'title': 'Senior VP of Finance & Accounting', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Pete  De Spain', 'title': 'Executive Vice President of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Teresa Brophy Bair Esq., J.D.', 'age': 52, 'title': 'Chief Legal Officer & Corporate Secretary', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Roger  Bakale Ph.D.', 'title': 'Senior Vice President of Manufacturing & Supply Chain', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Maureen  Clancy M.B.A.', 'title': 'VP and Global Head of Program Leadership & Project Management', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mollie  Leoni M.D.', 'title': 'Executive Vice President of Clinical Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brian T. Powl M.B.A., M.S.', 'age': 49, 'title': 'Chief Commercial Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§7
compensationRisk§7
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.864
currency§USD
dateShortInterest§1702598400
forwardEps§-2.27
pegRatio§-0.38
exchange§NMS
quoteType§EQUITY
shortName§Kura Oncology, Inc.
longName§Kura Oncology, Inc.
firstTradeDateEpochUtc§1442410200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d959d119-9140-35ab-8205-a916e1fac9db
gmtOffSetMilliseconds§-18000000
targetHighPrice§37.0
targetLowPrice§10.5
targetMeanPrice§28.5
targetMedianPrice§31.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§11
quickRatio§16.585
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
